Loading
A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab, Daratumumab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT06577025 by Janssen Research & Development, LLC, with 43 participants enrolled, started 2024-08-20 and due to reach its primary completion in 2030-09-02. Interventions recorded: Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Talquetamab, Teclistamab, Daratumumab, Lenalidomide.
Shares Talquetamab, Ciltacabtagene autoleucel, Johnson & Johnson, T-cell engagers (bispecific).
Shares Talquetamab, Teclistamab, Bortezomib, Johnson & Johnson.
Shares Ciltacabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide.
Shares Talquetamab, Daratumumab, Johnson & Johnson, PROTACs & molecular glues (targeted protein degradation).
Shares Talquetamab, Teclistamab, Johnson & Johnson, T-cell engagers (bispecific).
Shares Ciltacabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide.
Shares Daratumumab, Bortezomib, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).